NCT06572267View on ClinicalTrials.gov

Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

March 1, 2026

Conditions
Coronary Artery Disease
Interventions
DRUG

Mepolizumab low dose group

Meperizumab (0.05 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.

DRUG

Mepolizumab middle dose group

Meperizumab (0.1 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.

DRUG

Mepolizumab high dose group

Meperizumab (0.2 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.

DRUG

Saline

Intravenous infusion of saline 100 mL shall be completed within 30 to 60 min.

Trial Locations (1)

710032

RECRUITING

Ling Tao, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER